title: [Analysis of central mechanisms involved in gastric mucosal integrity].
abstract: Beta-endorphin, deltorphin II, [D-Ala2, Phe4, Gly5-ol-enkephalin (DAGO) as well as endomorphin-1 and endomorphin-2 injected intracerebroventricularly (i.c.v.) induced gastroprotective action. It has been raised that endogenous opioids may have a central role in maintaining gastric mucosal integrity. Therefore we aimed to study the role of endogenous opioid system in the gastroprotective action induced by activation of alpha 2-adrenoceptors, nociceptin- and cannabinoid-receptors. Our results suggest that the non-selective opioid receptor antagonist naloxone (27 nmol i.c.v.) and the delta-opioid receptor antagonist naltrindole (5 nmol i.c.v.) abolished the mucosal protective effect of alpha 2-adrenoceptor agonists clonidine (470 pmol i.c.v.) and rilmenidine (45 pmol i.c.v.), nociceptin (1 nmol i.c.v.) and the cannabinoid receptor agonist anandamide (110 nmol i.c.v.). Based on our findings it can be raised that opioid system besides its well known regulatory functions might be involved in maintenance of gastric mucosal integrity.
authors.affiliation: Farmakológiai és Farmakoterápiás Intézet, Semmelweis Egyetem, Altalános Orvostudományi Kar, Budapest. gyirkla@pharma.sote.hu
authors.forename: Klára
authors.initials: K
authors.lastname: Gyires
authors.forename: Zoltán
authors.initials: Z
authors.lastname: Zádori
mesh_terms: D000818:Animals; D001095:Arachidonic Acids / Q000494:pharmacology; D003000:Clonidine / Q000494:pharmacology; D063388:Endocannabinoids; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)- / Q000378:metabolism; D000431:Ethanol / Q000009:adverse effects; D018846:Excitatory Amino Acids / Q000819:agonists; D005753:Gastric Mucosa / Q000187:drug effects* / Q000378:metabolism*; D007276:Injections, Intraventricular; D008297:Male; D009270:Naloxone / Q000494:pharmacology; D009271:Naltrexone / Q000031:analogs & derivatives / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology*; D018377:Neurotransmitter Agents / Q000378:metabolism / Q000494:pharmacology*; D009842:Oligopeptides / Q000378:metabolism; D018847:Opioid Peptides / Q000378:metabolism; D010080:Oxazoles / Q000494:pharmacology; D053284:Polyunsaturated Alkamides / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D011957:Receptors, Opioid / Q000187:drug effects / Q000378:metabolism*; D000077769:Rilmenidine; D013276:Stomach Ulcer / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism*; D001615:beta-Endorphin / Q000378:metabolism; D000097629:Nociceptin
chemical_list: D001095:Arachidonic Acids; D003000:Clonidine; D063388:Endocannabinoids; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; D000431:Ethanol; D018846:Excitatory Amino Acids; D009270:Naloxone; D009271:Naltrexone; D009292:Narcotic Antagonists; D018377:Neurotransmitter Agents; D009842:Oligopeptides; D018847:Opioid Peptides; D010080:Oxazoles; D053284:Polyunsaturated Alkamides; D011957:Receptors, Opioid; D000077769:Rilmenidine; D001615:beta-Endorphin; D000097629:Nociceptin; C105293:endomorphin 1; C060209:deltorphin II, Ala(2)-; C105294:endomorphin 2; C055382:naltrindole; C078814:anandamide